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U.EUmyamtDr.Lipicky,theFoodaQdDNgAdQlii 
tration still requires that placebo-controlled Stbdies be per- 
formed for the approval of new drug!% However, most 
patients are now mceiving a~giote~si~4o~verti~g enzyme
iQbiMors tar heart failure. How can we carry out pbicebo- 
WQtrolledtrialsatthepRSQttkQe? 
RLi@y:Youcanperfinmaphce~trol!=dtrialin 
whichaUpatie~tsreceivea~angioteQsi~umvertingeenzyme 
inhibitor and the new drug or placebo is added to the 
regimen.Ifthenewdngisbetterthanplaceboinsucha 
study,itwiHbecleartbattbenewdtugise&ctive. 
ofclinical triala indicate hat drugs have dbectionally similar 
eifects on morbidity and mortality, whereas therapy may 
have dittbrent eifects on symptoms and mortality. I do not 
yetknowofanexampleofaheartfailuredrugthatlessened 
morbidity but worsened mortality. Would you consider 
using Mty as an approvable outcome rather than 
relying cm the results of an exercise t st? 
U.~Suchatrialisdesiitolookforan 
additive e&t. This approa& would not be able to evaluate 
anewdrugthatwasshnilartoorexhMedanegative 
i~tem&~witha~a~giotensinconvertiqgenxymeinhiitor. 
It. LipMty: I do not think one should measure the eifects 
of a dtug on morbidity instead ofon exercise tolerance. I 
wouklmeasurethee&tsofthedntgonmorbidityin 
addition toexercise t&rance. One measure ofe&acy is not 
Moe important than another. If we know the effects of a 
dw on morbidity and mortality, it is still important to
valuate he etf’ects of the drug on symptoms and exercise 
tolerance. 
I&IJpicky:Idonotknowifthereisasknplewayof 
deaiing with the problent. If one canies out a placebo 
controlled xercise toierance trial in which all patients are 
receiving diixin, diuretic dtugts and an an@otensin- 
converting enxynle iQhlMor, one can as!&l patients ran- 
domlytoplaceboor~vednyl.Ifthestudyshowsthatthe 
gmupreceiviQgactivetherapyexercisedkmgerthaQthe 
gtuupteceivingpiacebo,onehasleamedsometbingabout 
thenewdntgIftheplaceboandthea&egtoupswere 
similartoeachother,onehasalsoleamedthatthereisno 
obvicusadvaQtageofaddiQgthestudydnlgtostaQdard 
therapy.Hence,suchatrialcanproducetwooutcomesthat 
can be detlnitively interpMed. 
I disacgee that exercise tolerance is a surrogate end point 
for symptoms. Instead, exercise intolerance is an essential 
component of the heart failure syndrome; it is a diit 
measure of something that matters tothe patient. It is also 
one of the few simple ways of evaluating the ability of the 
heartto respond when ked with a demand for increased 
performance. 
Most important, we need to understand as much as we 
canabouta~drugandmeasureitseffectsanasmaay 
aspectsaftheheartfailuresyndro~aswecan.Thedata 
basethatisp&ucedbytheseeffortssbouldbeiutemally 
con istent. 
Ofcomse,ifthestudydrugisnotdiRrentfromplacebo 
ias~batrial,itisstiu~blethatthestudydrugmightbe 
~~toreplaceoQeoraUofthestandardmedi&ons. 
However,todrawsuchaconchu3ioQ,onewouidneedto 
conductatriaiinwhichoueormoteofthestandard 
medications were replaced by the study dtug, using an 
active-controlled desiga. CertaMy. we would need compel- 
lins evidence that he study m is likely to perlbrm as well 
as or better than standard therapy. Alternatively, the study 
could be conducted in patients who had not yet shown 
benefit t  standard therapy. I appre&te that he problems 
are not easy to resolve and that the present approach may 
~Owustomissektivedrugsf0rheartfailure. 
8. Ymn& I am specifIcaiiy thinking of a situation i  which 
anewdrugisdevelopedtbatactsbyapathwaynimilarto 
at of an established drug but has a d&rent side effect 
protie. The number of patients tef@red to show that he two 
dqsaresimilarintheiiefkctsonmortaliiislikelytobe 
very large, perhaps a  b as lO,ooO patients. However, if 
wecompa&theetkctsofthetwodrugsonmorbidityas 
well as mortality, we would need a much smaller sample 
Sk?& 
L Upkkyz 1 have no problem with the evaluation f 
morbkbty or with the use of a conSned morbidity and 
nmrtahty end point. I would have a problem if exercise 
tolerance had not been evaluated duriw the development of 
the drug. 
s. yti Dr. Lipicky, clinical trials aB generally de 
Wed to evaluate he eikct of treatment onsymptoms or 
M.~:Iwouldliketomaketwopoints.Ffrst,Ithink 
mortal but b~ are kmMate end points that may IX 
that we need to clarify the precise issues involved inthe 
of due, partkuW Cardbvascular mobSty. The results 
requkment fop a pkeb0-conNkd trial. The regukory 
requirementfortheapprovalofanewdrugforheartfailure 
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is not for a placebo-controlled stu y but for an adequate and 
well controlled study. One could carry out an active con- 
trolled trial, but it is very ditlicuk to interpret an active 
controlled trial if the two treatments are not different from 
each other. Consequently, we should be performing placebo- 
controlled trials for the evaluation f new drugs. However, a 
placebo-cot~trolRd trial oes not mean a trial carried out 
without background therapy. A placebo-controlled trial re- 
fers to the type of comparison not to the specifics ofthe 
background medications. If one defines a placebo-controlled 
trial as one carried out without background therapy, then 
there have been o phtceboumtrolled trials in the history of 
heart failure studies, because allof the studies with convert- 
ing enzyme inhibitors enrolled patients who were already 
teceivinq background therapy with dii and diuretic drugs. 
Second, it is important to evaluate clinically relevant end 
points in clinical studies. A clinically relevant end point is 
one that reflects how patients feel or how long they live. In 
this regard, exercise t sting isa clinically relevant end point, 
because it is a measure of how well patienr 5 can perform 
exercise-and in many ways, heart faihue can be de&d in 
terms of how it impedes the ability to exercise. I think that it 
is good idea to measure the symptoms of heart failure and 
quality of life of peptients with heart failure, but these are 
closely &ted to exercise tolemnce. There has yet to be an 
example ofa drug for heart tilure that lessened symptoms 
and did not improve exercise tolerance. 
R. UpIcky: There is enalapril. 
M. 3acke~ Enalapril has been shown to improve quality 
of life and exercise tolerance in two placebo-contro&d 
trial& 
5;. Yusufz Dr. Guyatt, one of the problems we face in 
carrying out trials in patients with heart failure is the high 
rate of attrition, which is higher than that of any other 
disease incardiology. In the SOLVD trial, we found that 
atter 6 weeks, quality of life was significantly better in the 
active treatment group. However, this e&t was no longer 
apparent after 12 months, presumably because differeat 
types of patients were alive in the two treatment groups. 
Have you found a way of hand&g the issue of competing 
risks? 
G. Guyatt: For nonmortality binary end points, one 
solution to the prob!em lies in wmbining the end points. By 
adding quantity o quality of life, it is possible todevelop a 
measure of quality of liife;ldusted lie-years. 
R. Lipkky: We have not seen clear benefit on quality of 
life with any agent for heart failure. Can you explain that? 
G.GuyattzAsfarasIknow,attemptstomeasurequality 
of lie have been carried out with drugs that do not work. For 
drugs that do work, it has been easier to demonstrate th ir 
utility by measuring their elfects on morbidity and mortality, 
whereas the development of quality of lie instruments is still 
in its infancy. 
